Lexaria Bioscience Corp. (LEXX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lexaria Bioscience Corp. (LEXX:NASDAQ), powered by AI.

Current Price
$0.59
P/E Ratio
-0.9
Market Cap
11M
Sector
Healthcare
What is the Lexaria Bioscience Corp. stock price forecast?

Lexaria Bioscience Corp. is currently trading at $0.59. View real-time AI analysis on Alpha Lenz.

What is Lexaria Bioscience Corp. insider trading activity?

View the latest insider trading data for Lexaria Bioscience Corp. on Alpha Lenz.

What is Lexaria Bioscience Corp.'s P/E ratio?

Lexaria Bioscience Corp.'s P/E ratio is -0.9.

Lexaria Bioscience Corp.

NASDAQ · LEXX
$0.59-0.02(-2.81%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Lexaria Bioscience Corp.'s future dividend policy...
Alpha Chat Insight

Lexaria Bioscience Corp. trades at a P/E of -0.9 (undervalued) with modest ROE of -215.9%. 3Y revenue CAGR of 40.3% highlights clear growth momentum.

Ask for details

Company Overview

Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the delivery of bioactive compounds, including cannabinoids and nicotine, through its proprietary drug delivery platform, DehydraTECH. The primary function of this platform is to improve the speed and efficiency of oral absorption of active pharmaceutical ingredients, with potential applications extending across a wide range of industries, including pharmaceuticals, nutraceuticals, consumer packaged goods, and more. Lexaria's technology aims to provide alternative product formulations that offer improved bioavailability and taste masking without altering the stimulant properties of the active compounds. By operating at the intersection of drug development and consumer health, the company plays a pivotal role in advancing innovative delivery solutions, contributing to the growing market of next-generation wellness products. Lexaria Bioscience Corp. continues to partner with organizations intent on developing products that integrate its advanced technology, seeking to capitalize on emerging markets where efficient delivery systems for bioactive substances are increasingly in demand.

CEOMr. Richard C. Christopher
SectorHealthcare
IndustryBiotechnology
Employees7

Company Statistics

FY 2025

Profile

$10.60MMarket Cap
$705.92KRevenue
0.00Shares Out
7Employees

Margins

99.61%Gross
-1665.79%EBITDA
-1683.01%Operating
-1687.36%Pre-Tax
-1687.36%Net

Valuation

-0.89P/E
3.55P/B
15.02EV/Sales
-0.72EV/EBITDA
-1.00P/FCF

Growth (CAGR)

40.34%Rev 3Yr
12.92%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-182.65%ROA
-215.88%ROE
-182.18%ROIC

Financial Health

$1.80MCash & Cash Equivalents
$-229.76KNet Debt
60.41%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Lexaria Bioscience Corp. (ticker: LEXX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 7 employees. Market cap is $11M.

The current price is $0.589 with a P/E ratio of -0.89x and P/B of 3.55x.

ROE is -215.88% and operating margin is -1683.01%. Annual revenue is $705,923.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Lexaria Bioscience Corp. (LEXX) Stock Forecast 2026 $0.59 — Price, Financials & Analyst Targets | Alpha Lenz